Securian Asset Management Inc. Sells 5,177 Shares of Medtronic PLC $MDT

Securian Asset Management Inc. reduced its position in Medtronic PLC (NYSE:MDT) by 7.7% during the third quarter, HoldingsChannel.com reports. The firm owned 61,877 shares of the medical technology company’s stock after selling 5,177 shares during the period. Securian Asset Management Inc.’s holdings in Medtronic were worth $5,893,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of MDT. AXQ Capital LP grew its position in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares in the last quarter. Legacy Advisory Services LLC purchased a new stake in Medtronic in the first quarter worth about $541,000. GC Wealth Management RIA LLC lifted its stake in Medtronic by 20.6% in the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after acquiring an additional 5,734 shares during the period. Merit Financial Group LLC grew its holdings in Medtronic by 37.5% during the 2nd quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock worth $4,972,000 after acquiring an additional 15,561 shares in the last quarter. Finally, Verdence Capital Advisors LLC increased its position in Medtronic by 22.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after purchasing an additional 5,296 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent research reports. Truist Financial dropped their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Jefferies Financial Group reissued a “hold” rating and issued a $110.00 price target on shares of Medtronic in a research report on Wednesday, November 19th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Monday. Finally, Sanford C. Bernstein set a $111.00 target price on Medtronic in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Price Performance

Shares of MDT stock opened at $100.27 on Wednesday. The firm has a market capitalization of $128.54 billion, a price-to-earnings ratio of 27.03, a PEG ratio of 2.57 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock’s 50-day simple moving average is $97.85 and its 200-day simple moving average is $94.31. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business earned $1.26 EPS. Medtronic’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).